NEW YORK (360Dx) – GenMark Diagnostics said after the close of the market on Monday that its second quarter revenues increased 20 percent year over year, beating the consensus Wall Street estimate on the top line but missing the estimate on the bottom line.

For the three months ended June 30, GenMark posted $14.9 million, up from $12.4 million, and beating the analysts' average estimate of $14.5 million. Product revenues came in just below $14.9 million compared to $12.3 million a year ago, while license and other revenues increased to $74,000 from $68,000.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.